Virtuvax 1 Nov. in Pivot Park Oss

Meet Virtuvax in Pivot Park Oss @HollandBIO - Topsector cross-over event on 1 November 2016.

For information of the event see: Topsector-cross-over-event

Virtuvax for collaboration on your innovation in vaccine development or your biosimilar

Virtuvax' innovation in vaccine industry “vaccine development skating on start-ups”

Mucosis Announces Re-issue of Major Patent by US Patent Office USPTO

SynGEM publication paper of the month on ReSViNET

First-in-Human Results of SynGEM Demonstrate that the RSV Vaccine Is Well-Tolerated and Capable of I

New comment by UMC Utrecht on the SynGEM vaccine trial is a plea to consider the vaccine in an RSV c

Phase I clinical trial data of Mucosis intranasal vaccine against respiratory syncytial virus (RSV)

Virtuvax to attend DCVMN in Kunming

Virtuvax for collaboration on your innovation in vaccine development or your biosimilar

Matchmaking and contributing to a vaccine based Global insurance against Emerging Infections?

Virtuvax' innovation in vaccine industry “vaccine development skating on start-ups”

Meet Virtuvax @ BioWin Day 2016